Quality assessment of autologous hematopoietic blood progenitor and stem cell grafting: A prospective registration study

Journal of Biological Regulators and Homeostatic Agents

Volumn 16, Issue 4, 2002, Pages 272-288

  Johnsen, Hans E ^a   Lanza, Francesco ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AUTOTRANSPLANTATION; BLOOD TOXICITY; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFIDENTIALITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DERMATITIS; ENTERITIS; FEVER; FLOW CYTOMETRY; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MUCOSA INFLAMMATION; MULTICENTER STUDY; POSTOPERATIVE CARE; PROBABILITY; PROSPECTIVE STUDY; QUALITY CONTROL; REGISTRATION; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; STEM CELL MOBILIZATION;

EID: 0036820957     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Serke S and Johnsen HE on behalf of the EBMT subcommittee on "Quality assessment of haematopoietic stem cell grafts". A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-70.
2. + stem cell enumeration using stable test material, standard protocols and targeted training.CD34 Task Force of the European Working Group of Clinical Cell Analysis (EWGCCA). Br J Haematol 2000; 108: 784-9.
3. Serke S, Johnsen H, Huhn D, et al. European survey of the flow cytometric determination of CD34-expression cells. Cytotherapy 1999; 1: 343-7.
4. The Joint Accreditation Committee of ISHAGE-Europe and EBMT. Standards for blood and marrow progenitor cell processing, collection and transplantation 1998.
5. Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-70.
6. Krause DS, Fackler MJ, Civin CI, et al. CD34: structure, biology, and clinical utility. Blood 1996; 87: 1-13.
7. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157.
8. Serke S, Sauberlich S, Huhn D. Multiparameter flow-cytometrical quantitation of circulating CD34(+)-cells: correlation to the quantitation of circulating haemopoietic progenitor cells by in vitro colony-assay. Br J Haematol 1991; 77: 453-9.
9. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-9.
10. Fritsch G, Emminger W, Buchinger P, et al. CD34 analysis in peripheral blood correlates with colony forming capacity-an update. Prog Clin Biol Res 1992; 377: 531-6.
11. Ravagnani F, Siena S, Bregni M, et al. Methodologies to estimate circulating hematopoietic progenitors for autologous transplantation in cancer patients. Haematologica 1991; 76 (Suppl. 1): 46-9.
12. Hematopoietic Stem Cells. The Mulhouse Manual. In: Wunder E, Sovalat H, Henon P, Serke S, eds. Alpha Med Press, 1994: 1-317.
13. Wunder E, Sovalat H, Fritsch G, et al. Report on the European Workshop on Peripheral Blood Stem Cell Determination and Standardization-Mulhouse, France, February 6-8 and 14-15, 1992. J Hematother 1992; 1: 131-42.
14. Inaba T, Shimazaki C, Ashihara E, et al. Two-color flow cytometric analysis of CD34-positive peripheral blood stem cells mobilized by recombinant human granulocyte- colony stimulating factor for autotransplantation. Prog Clin Biol Res 1992; 377: 561-7.
15. Read EJ, O'Shaughnessy JA, Yu MY, et al. Flow cytometric quantitation of circulating hematopoietic progenitor cells in breast cancer patients on chemotherapy. Prog Clin Biol Res 1992; 377: 523-30.
16. Bender JG, Williams SF, Myers S, et al. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant 1992; 10: 281-5.
17. + peripheral blood hematopoietic progenitors for autografting in cancer patients. Int J Artif Organs 1993; 16 (Suppl. 5): S80-2.
18. + cells mobilized to the peripheral blood during the recovery from cyclophosphamide chemotherapy. Prog Clin Biol Res 1992; 377: 575-82.
19. + hematopoietic stem cells [see comments]. J Hematother 1996; 5: 227-236.
20. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-26.
21. Serke S, Arseniev L, Watts M, et al. Imprecision of counting CFU-GM colonies and CD34-expressing cells. Bone Marrow Transplant 1997; 20: 57-61.
22. + cells be analysed? A study of three classes of antibody and five leucocyte preparation procedures. J Immunol Methods 1997; 204: 175-88.
23. Lowdell MW, Bainbridge DR. External quality assurance for CD34 cell enumeration-results of a preliminary national trial. Royal Microscopical Society Clinical Flow Cytometry Group QA Schemes. Bone Marrow Transplant 1996; 17: 849-53.
24. Urashima M, Ohkawara J, Hoshi Y, et al. Peripheral blood progenitor cell transplantation estimated by three-colour (CD34, HLA-DR, CD33) flow cytometry. Acta Haematol 1994; 92: 23-8.
25. Knape CC. Standardization of absolute CD34 cell enumeration [letter; comment]. J Hematother 1996; 5: 211-2.
26. + cell estimation in leucapheresis products. Bone Marrow Transplant 1996; 18: 791-6.
27. Remacha AF, Martino R, Sureda A, et al. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Bone Marrow Transplant 1996; 17: 163-8.
28. + cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCLG). J Hematother 1996; 5: 237-45.
29. + Cell Enumeration in Blood and Autografts: Report from the Third Workshop. J Hematother 1999; 8: 15-28.
30. + cell counts to guide timing and yield of large-scale collection by leukapheresis. J Hematother 1998; 7: 45-52.
31. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
32. Knudsen LM, Gaarsdal E, Jensen L, et al. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. J Hematother 1996; 5: 399-406.
33. Bolwell BJ, Goormastic M, Andresen S, et al. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count. Bone Marrow Transplant 1997; 20: 459-63.
34. Lowenthal RM, Faberes C, Marit G, et al. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22: 763-70.
35. + cell dose. Bone Marrow Transplant 1999; 23: 1237-43.
36. Reiffers J, Faberes C, Boiron JM, et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994; 3: 185-91.
37. Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor- mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-86.
38. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-7.
39. Schwartzberg L, Birch R, Blanco R, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-74.
40. Morton J, Morton A, Bird R, et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res 1997; 21: 21-7.
41. Haas R, Witt B, Mohle R, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-61.
42. Steen R, Tjonnfjord GE, Gaudernack G, et al. Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. Br J Haematol 1996; 94: 597-605.
43. Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. J Hematother 1992; 1: 115-29.
44. Civin CI, Almeida-Porada G, Lee MJ, et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88: 4102-9.
45. + cells measured under conditions that prevent P-selectin-mediated binding of platelets. Blood 1995; 86: 3771-82.
46. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995; 13: 1922-32.
47. + cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation. Clin Immunol Immunopathol 1994; 70: 10-8.
48. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony- stimulating factor. Blood 1994; 84: 2795-801.
49. Baech J, Johnsen HE. Technical aspects and clinical impact of hematopoietic progenitor subset quantification. Stem Cells 2000; 18: 76-86.
50. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58.
51. van der WE, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size [see comments]. Ann Oncol 1994; 5: 795-802.
52. Olivieri A, Offidani M, Montanari M, et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329-37.
53. + cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715-22.
54. Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-55.
55. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
56. + cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999; 23: 1177-81.
57. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
58. Watts MJ, Sullivan AM, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 1998; 16: 1554-60.
59. + cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1996; 18: 871-8.
60. + cell dose requirements for rapid engraftment in a sequential high- dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. J Hematother Stem Cell Res 1999; 8: 357-63.
61. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-94.
62. Haynes A, Hunter A, McQuaker G, et al. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of GCSF. Bone Marrow Transplant 1995; 16: 359-63.
63. Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996; 14: 1114-21.
64. + cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663-70.
65. + hematopoietic progenitor cells. Cytometry 1998; 34: 264-71.
66. + hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998; 34: 128-42.
67. Sovalat H, Wunder E, Tienhaara A, et al. Commentary: prospects for standardization of stem cell determination within Europe. J Hematother 1993; 2: 293-6.
68. Verwer BJH, Ward DM. An automated classification algorithm for ProCOUNT TM flow cytometric acquisition and analysis. J Hematother 1997; 6: 169.
69. + hematopoietic progenitor cells in peripheral blood and leukapheresis products by microvolume fluorimetry: a comparison with flow cytometry. J Hematother 1997; 6: 291-301.
70. + cells. Transfusion 1999; 39: 864-72.
71. Gisselø CG, Roer O, Hoffmann MH, Hansen MB, Taaning E, Johnsen HE. Assessing agreement between CD34 enumeration by flow cytometry and volumetric analysis. Bone Marrow Transplant 2002; 29: 699-703.
72. + subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF [letter] [see comments]. Bone Marrow Transplant 1998; 21: 1167-9.
73. Larsson K, Bjorkstrand B, Ljungman P. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation. Support Care Cancer 1998; 6: 378-83.
74. Eastern Cooperative Oncology Group, ECOG. Common Toxicity Criteria. www.ecog.dfci.harvard.edu. 2000.
75. + stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation. Br J Haematol 1998; 102: 553-65.
76. + haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol 1999; 21: 301-8.
77. + stem cell enumeration using stable test material, standard protocols and targeted training. CD34 Task Force of the European Working Group of Clinical Cell Analysis (EWGCCA). Br J Haematol 2000; 108: 784-92.
78. Baech J, Roer O, Johnsen HE for the Nordic Stem Cell Laboratory Group (NSCL-G). Individual quality assessment of autografting by probability evaluation: a model estimated by analysis of graft-related end points in 204 patients with malignancies. Bone Marrow Transplant 2003; 00: 1-6.